关于回购股份比例达到 1%的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、吉林省西点药业科技发展股份有限公司（以下简称"公司"）拟使用自 有资金和/或自筹资金不低于人民币 2,500 万元（含）且不超过人民币 5,000 万 元（含）以集中竞价交易方式回购公司已发行的人民币普通股（A 股）股票，用 于实施员工持股计划或股权激励，回购价格不超过人民币 42.00 元/股（含）， 回购期限为自董事会审议通过本次回购股份方案之日起 12 个月内，具体回购股 份的数量以回购期限届满时实际回购的股份数量为准。具体内容详见公司于 2026 年 2 月 10 日在巨潮资讯网（www.cninfo.com.cn）披露的《回购股份报告 书》。 2、公司已于 2026 年 1 月 22 日召开第八届董事会第十四次会议，审议通过 了《关于回购公司股份方案的议案》。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等有关规定，回购股份占上市公司总股本的比例每增加 1% 的，应当在事实发生之日起三个交易日内予以披露 ...

证券代码：301130 证券简称：西点药业 公告编号：2026-013 吉林省西点药业科技发展股份有限公司 关于首次回购公司股份暨回购股份进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、公司未在下列期间回购公司股份 1、吉林省西点药业科技发展股份有限公司（以下简称"公司"）拟使用自 有资金和/或自筹资金不低于人民币 2,500 万元（含）且不超过人民币 5,000 万 元（含）以集中竞价交易方式回购公司已发行的人民币普通股（A 股）股票，用 于实施员工持股计划或股权激励，回购价格不超过人民币 42.00 元/股（含）， 回购期限为自董事会审议通过本次回购股份方案之日起 12 个月内，具体回购股 份的数量以回购期限届满时实际回购的股份数量为准。具体内容详见公司于 2026 年 2 月 10 日在巨潮资讯网（www.cninfo.com.cn）披露的《回购股份报告 书》。 2、公司已于 2026 年 1 月 22 日召开第八届董事会第十四次会议，审议通过 了《关于回购公司股份方案的议案》。 根据《上市公司股份回购规则》《深圳证券交易 ...

Group 1 - The company, Xiduan Pharmaceutical, has announced a share repurchase plan with a total amount between 25 million and 50 million yuan, at a price not exceeding 42 yuan per share, aimed at employee stock ownership or equity incentives [1][2] - The repurchase will be conducted through centralized bidding and is set to occur within 12 months from the board's approval [2] - Financial data indicates that for the first three quarters of 2025, the company's operating revenue decreased by 1.89% year-on-year, and the net profit attributable to shareholders fell by 2.70% year-on-year [3]

Core Viewpoint - The company plans to repurchase its shares through a centralized bidding process, with a total amount between 25 million and 50 million yuan, at a price not exceeding 42 yuan per share [1] Group 1 - The repurchase will be used for implementing an employee stock ownership plan or equity incentive [1] - The repurchase period is set for 12 months from the date the board of directors approves the share repurchase plan [1]

证券代码：301130 证券简称：西点药业 公告编号：2026-012 吉林省西点药业科技发展股份有限公司 回购股份报告书 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、吉林省西点药业科技发展股份有限公司（以下简称"公司"）拟使用自 有资金和/或自筹资金不低于人民币 2,500 万元（含）且不超过人民币 5,000 万 元（含）以集中竞价交易方式回购公司已发行的人民币普通股（A 股）股票，用 于实施员工持股计划或股权激励，回购价格不超过人民币 42.00 元/股（含）， 回购期限为自董事会审议通过本次回购股份方案之日起 12 个月内，具体回购股 份的数量以回购期限届满时实际回购的股份数量为准。 2、公司已于 2026 年 1 月 22 日召开第八届董事会第十四次会议，审议通过 了《关于回购公司股份方案的议案》。 3、根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等 相关规定，公司已在中国证券登记结算有限责任公司深圳分公司开立了回购专用 证券账户，该账户仅用于回购公司股份。 相关风险提示： 1、本次回购股份方案存在回购期限 ...

Core Viewpoint - The company has successfully completed the registration of its wholly-owned subsidiary, Xidian Pharmacy Co., Ltd., in Panshi City, with a registered capital of 2 million RMB [1]. Group 1: Company Announcement - The company held its 14th meeting of the 8th Board of Directors on January 22, 2026, where it approved the establishment of a wholly-owned subsidiary [1]. - The subsidiary, Xidian Pharmacy, has been officially registered and has obtained a business license from the Panshi City Market Supervision Administration [1][2]. - The registered capital of Xidian Pharmacy is 2 million RMB, and it is classified as a limited liability company [1]. Group 2: Business Scope - The business scope of Xidian Pharmacy includes retail of pharmaceuticals, third-class medical devices, and sales of disinfectants, among other activities [1]. - The subsidiary is authorized to engage in various sales activities, including food sales, health food sales, and retail of medical masks [1].

证券代码：301130 证券简称：西点药业 公告编号：2026-011 吉林省西点药业科技发展股份有限公司 吉林省西点药业科技发展股份有限公司（以下简称"公司"）于 2026 年 1 月 22 日召开了第八届董事会第十四次会议，审议通过了《关于拟设立全资子公 司的议案》，同意公司拟使用自有资金 200 万元人民币在吉林省磐石市投资设立 全资子公司西点大药房有限公司（暂定名，最终以市场监督管理部门核准结果为 准，以下简称"西点大药房"），并授权公司管理层办理西点大药房的设立登记 事宜。授权有效期自董事会审议通过之日起至工商变更登记及章程备案办理完毕 之日止。具体内容详见公司在巨潮资讯网上披露的《关于拟设立全资子公司的公 告》（公告编号：2026-006）。 近日，公司完成了相关工商登记手续，并取得了磐石市市场监督管理局颁发 的《营业执照》。相关工商登记信息如下： 名称：磐石市西点大药房有限责任公司 统一社会信用代码：91220284MAK5NLRP75 类型：有限责任公司（自然人投资或控股的法人独资） 关于磐石子公司完成工商登记并取得营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 ...

证券代码：301130 证券简称：西点药业 公告编号：2026-010 吉林省西点药业科技发展股份有限公司 关于回购股份事项前十名股东及前十名无限售条件 注 1：以上股东的持股数量为合并普通账户和融资融券信用账户后的总持股数量。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号—-回购股份》等相关法律法规及规范性文件的规定，现将公司董事会公告 回购股份决议的前一个交易日（即 2026 年 1 月 21 日）登记在册的前十名股东和 前十名无限售条件股东的名称、持股数量和持股比例情况公告如下： 序号 股东名称 持股数量(股) 占总股本比例(%) 1 张俊 19,627,034.00 25.66 2 鼎典投资管理（北京）有限公司－横琴鼎典 股权投资基金合伙企业（有限合伙） 6,013,154.00 7.86 3 珠海横琴岩合健康科技有限公司 3,697,400.00 4.83 4 国投高科技投资有限公司 1,883,997.00 2.46 一、董事会公告回购股份决议前一个交易日前十名股东持股情况 | 5 | 石英秀 | 1,554,017.00 | 2.03 | | --- | --- | ...

Group 1 - The company has approved a share repurchase plan to buy back its issued A-shares using its own and/or self-raised funds, with a maximum price of RMB 42.00 per share and a total fund amount between RMB 25 million and RMB 50 million [1] - The estimated number of shares to be repurchased is approximately 595,238 to 1,190,476 shares, which accounts for about 0.78% to 1.56% of the company's total share capital [1] - The implementation period for the share repurchase is within twelve months from the board's approval date [1] Group 2 - The company has obtained a loan commitment from China Construction Bank for the share repurchase, with a maximum loan amount not exceeding RMB 45 million [3] - The loan term is set for three years, specifically for the purpose of repurchasing the company's listed shares [4][5] - The loan commitment becomes effective upon signature and seal by the bank's authorized representative and is valid until January 29, 2027 [5] Group 3 - The loan commitment provides financing support for the share repurchase, but does not guarantee the total repurchase amount, which will be determined based on actual funds used at the end of the repurchase [6] - The company will implement the repurchase plan based on market conditions and will fulfill its information disclosure obligations as required by laws and regulations [6]

Core Viewpoint - Multiple listed companies have disclosed their share repurchase progress, indicating a trend of companies actively engaging in buybacks to enhance shareholder value and stabilize stock prices [3][4][6][10]. Group 1: Company Repurchase Plans - Midea Group (000333) announced a plan to repurchase A-shares with a total amount not exceeding 3 billion yuan and not less than 1.5 billion yuan, with a maximum price of 100 yuan per share. As of January 31, 2026, the company had repurchased 26.94 million shares, accounting for 0.3545% of the total share capital, at an average price of 74.14 yuan per share, totaling approximately 1.998 billion yuan [3][4]. - SF Holding (002352) adjusted its repurchase plan to a total amount between 1.5 billion yuan and 3 billion yuan, with a maximum price of 60 yuan per share. As of January 31, 2026, the company had repurchased 48.29 million shares, representing 0.96% of the total share capital, at an average price of 39.34 yuan per share, totaling around 1.9 billion yuan [6]. - GoerTek (002241) increased its repurchase amount from a minimum of 500 million yuan to a minimum of 1 billion yuan, with a maximum of 1.5 billion yuan. As of February 2, the company had repurchased 40.55 million shares, accounting for 1.14% of the total share capital, at an average price of 27.29 yuan per share, totaling approximately 1.108 billion yuan [8]. Group 2: Termination of Repurchase Plans - Qinsun Holdings (002638) announced the termination of its plan to reduce repurchased shares, which was initially set to sell 16.49 million shares, representing 1.15% of the total share capital. The decision was made to stabilize the stock price and enhance investor confidence [10]. Group 3: Financial Support for Repurchase - Xidun Pharmaceutical (301130) disclosed that it obtained a commitment letter from a financial institution for a stock repurchase loan, with a total amount between 25 million yuan and 50 million yuan, and a maximum repurchase price of 42 yuan per share. The expected repurchase quantity is between 595,200 and 1,190,500 shares, accounting for 0.78% to 1.56% of the total share capital [12][14].